AR069281A2 - Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos - Google Patents

Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos

Info

Publication number
AR069281A2
AR069281A2 ARP080104921A ARP080104921A AR069281A2 AR 069281 A2 AR069281 A2 AR 069281A2 AR P080104921 A ARP080104921 A AR P080104921A AR P080104921 A ARP080104921 A AR P080104921A AR 069281 A2 AR069281 A2 AR 069281A2
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
same
sustained release
average molecular
molecular weight
Prior art date
Application number
ARP080104921A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069281(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR069281A2 publication Critical patent/AR069281A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion farmacéutica, que comprende fluvastatina o una sal farmacéuticamente aceptable de la misma, hidroxipropilmetilcelulosa y un polímero hidrofílico no ionico seleccionado del grupo formado hidroxietilcelulosa con un peso molecular promedio en numero de 90.000 a 1.300.000; hidroxipropilcelulosa con un peso molecular promedio en numero de 370.000 a 1.500.000; y poli(oxido de etileno) con un peso molecular promedio en numero de 100.000 a 500.000; y uso de la misma para preparar medicamentos. Reivindicacion 6: Una composicion farmacéutica de la reivindicacion 1, caracterizada porque comprende de 5 a 50 por ciento en peso de fluvastatina o una sal farmacéuticamente aceptable de la misma, basándose en el peso total de la composicion. Reivindicacion 12: Una composicion farmacéutica de la reivindicacion 1, caracterizada porque la proporcion en peso de hidroxipropilmetilcelulosa a polímero hidrofílico no ionico es de 10:1 a 3:1.
ARP080104921A 1998-10-14 2008-11-11 Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos AR069281A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14

Publications (1)

Publication Number Publication Date
AR069281A2 true AR069281A2 (es) 2010-01-13

Family

ID=22627919

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990105146A AR020780A1 (es) 1998-10-14 1999-10-12 Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo
ARP080104921A AR069281A2 (es) 1998-10-14 2008-11-11 Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990105146A AR020780A1 (es) 1998-10-14 1999-10-12 Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo

Country Status (30)

Country Link
EP (1) EP1121116B1 (es)
JP (2) JP2002527388A (es)
KR (1) KR100517090B1 (es)
CN (1) CN1196481C (es)
AR (2) AR020780A1 (es)
AT (1) ATE382345T1 (es)
AU (1) AU765475B2 (es)
BR (1) BR9911648A (es)
CA (1) CA2346868C (es)
CO (1) CO5140079A1 (es)
CY (1) CY1107874T1 (es)
DE (1) DE69937891T2 (es)
DK (1) DK1121116T3 (es)
ES (1) ES2297936T3 (es)
HK (1) HK1040920B (es)
HU (1) HUP0104268A3 (es)
ID (1) ID29350A (es)
IL (2) IL142375A0 (es)
MY (1) MY121105A (es)
NO (1) NO327285B1 (es)
NZ (1) NZ511010A (es)
PE (1) PE20001110A1 (es)
PL (1) PL198850B1 (es)
PT (1) PT1121116E (es)
RU (1) RU2259826C2 (es)
SK (2) SK286595B6 (es)
TR (1) TR200101088T2 (es)
TW (1) TW577738B (es)
WO (1) WO2000021525A2 (es)
ZA (1) ZA200103001B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093859A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
ATE361060T1 (de) * 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2004024184A1 (ja) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
JP2009527577A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム医薬組成物
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
SG11201505352RA (en) * 2013-01-09 2015-08-28 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CA3112205A1 (en) 2018-09-25 2020-04-02 Ponce De Leon Health Designated Activity Company Process for making calcium alpha-ketoglutarate
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
PL186907B1 (pl) * 1995-12-22 2004-03-31 Kowa Co Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
AU765475B2 (en) 2003-09-18
CA2346868A1 (en) 2000-04-20
NO20011695L (no) 2001-05-30
PT1121116E (pt) 2008-03-12
IL142375A0 (en) 2002-03-10
TR200101088T2 (tr) 2001-10-22
CA2346868C (en) 2008-09-09
ZA200103001B (en) 2002-07-11
RU2259826C2 (ru) 2005-09-10
DK1121116T3 (da) 2008-05-13
AR020780A1 (es) 2002-05-29
SK286596B6 (sk) 2009-01-07
HK1040920A1 (en) 2002-06-28
ES2297936T3 (es) 2008-05-01
NO20011695D0 (no) 2001-04-04
EP1121116B1 (en) 2008-01-02
JP4938383B2 (ja) 2012-05-23
BR9911648A (pt) 2001-03-20
JP2006298945A (ja) 2006-11-02
IL142375A (en) 2012-01-31
CY1107874T1 (el) 2013-06-19
JP2002527388A (ja) 2002-08-27
PL348109A1 (en) 2002-05-06
HK1040920B (zh) 2005-07-29
KR20010080156A (ko) 2001-08-22
PE20001110A1 (es) 2000-11-01
EP1121116A2 (en) 2001-08-08
SK5092001A3 (en) 2001-09-11
CN1328454A (zh) 2001-12-26
ATE382345T1 (de) 2008-01-15
AU6090999A (en) 2000-05-01
WO2000021525A2 (en) 2000-04-20
HUP0104268A3 (en) 2002-06-28
DE69937891T2 (de) 2008-12-11
ID29350A (id) 2001-08-23
DE69937891D1 (de) 2008-02-14
SK286595B6 (sk) 2009-01-07
CN1196481C (zh) 2005-04-13
NO327285B1 (no) 2009-06-02
KR100517090B1 (ko) 2005-09-27
CO5140079A1 (es) 2002-03-22
MY121105A (en) 2005-12-30
TW577738B (en) 2004-03-01
WO2000021525A3 (en) 2000-08-10
HUP0104268A2 (hu) 2002-04-29
NZ511010A (en) 2003-10-31
PL198850B1 (pl) 2008-07-31

Similar Documents

Publication Publication Date Title
AR069281A2 (es) Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos
AR010704A1 (es) Composiciones farmaceuticas en forma de particulas que comprenden tetrahidrolipstatina, un estabilizante y un excipiente
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
BR0312870A (pt) Comprimido de liberação sustentada compreendendo reboxetina
ATE515949T1 (de) Süssware
KR870003781A (ko) 지효성 조성물
AR030276A1 (es) Preparacion sustancialmente homogenea de proteina estimuladora de eritropoyetina (nesp) modificada quimicamente, composicion farmaceutica y uso para la fabricacion de un medicamento para tratar un desorden hematopoyetico
DK0736004T3 (da) (2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
ES2531326T3 (es) Sistemas de red polimérica para dispositivos médicos y métodos de uso
ES2097787T3 (es) Composicion farmaceutica para la administracion rectal de principios activos que presenta una accion de medicacion prevalentemente topica a nivel del colon.
WO2006026504A3 (en) Mucoadhesive oral formulations of high permeability, high solubility drugs
SV2002000969A (es) Composicion parenteral reconstituible
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
KR880009634A (ko) 슈도에페드린 브롬페니라민 요법의 개량
AR015482A1 (es) Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclita
CO5640149A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus sistematico eritematoso
RU2001111882A (ru) Фармацевтическая композиция с замедленным высвобождением фармацевтичесКи активного вещества и способ высвобождения фармацевтически активного вещества
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
AR047205A1 (es) Composiciones oftalmicas que contienen una combinacion sinergica de tres polimeros
DE602004009552D1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
KR900000076A (ko) 딜티아젬(diltiazem) 공급용의 제형(dosage form)
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
CO5170467A1 (es) Capsulas de eter de celulosa libres de turbiedad y proceso para hacer las mismas

Legal Events

Date Code Title Description
FC Refusal